Physician profile
Gregory Allen
NPI 1952398356
$23,240.87
in general payments reported to CMS, 2019-2025
67 companies · $3,543 in 2025
The $3,543 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,772 · 2020: $2,797 · 2021: $3,606 · 2022: $3,934 · 2023: $3,479 · 2024: $3,110 · 2025: $3,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,026.49 |
| Education | $105.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,891.49 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $2,832.93 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $1,826.82 | 2019-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,658.08 | 2019-2025 | Xifaxan, Cycloset, Trulance |
| Abbvie INC. | $1,570.46 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,320.53 | 2019-2025 | |
| Novo Nordisk INC | $1,189.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $986.16 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $802.17 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Sunovion Pharmaceuticals INC. | $701.71 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $517.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $413.56 | 2019-2024 | Verquvo, Dificid, Belsomra |
| Astellas Pharma US INC | $402.29 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $365.90 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.66 | 2024-2025 | Caplyta |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.